Effects of Co-supplementation with alpha-linolenic acid and L-carnitine on inflammatory status and oxidative stress in women with migraine: A randomized, triple-blind, placebo-controlled trial

• ALA and L-carnitine co-supplementation reduced inflammatory markers in migraine patients. • The intervention improved antioxidant capacity and decreased oxidative stress biomarkers. • Combined ALA and L-carnitine may offer synergistic benefits for migraine management. • First trial examining ALA + L-carnitine effects on inflammation/oxidative stress in migraine. Migraine is associated with inflammation and oxidative imbalance. This randomized controlled trial examined the effects of alpha-linolenic acid (ALA) and L-carnitine co-supplementation on inflammatory status and oxidative stress in 80 women with migraine. Serum markers were measured before and after the intervention. Compared to placebo, ALA and L-carnitine co-supplementation significantly reduced nitric oxide (−6.10; 95 % CI (−9.08, −3.12) vs. 1.77; 95 % CI (−3.21, 6.76) nmol/mL, P = 0.038), malondialdehyde (−5.47; 95 % CI (−6.33, −4.62) vs. −0.15; 95 % CI (−0.50, −0.20) nmol/mL, P = 0.011), and C-reactive protein (−0.44; 95 % CI (−0.47, −0.41) vs. −0.02; 95 % CI (−0.05, 0.007) mg/L, P = 0.007) levels. It also increased total antioxidant capacity (185.60; 95 % CI (159.69, 211.50) vs. 5.22; 95 % CI (−29.21, 39.66) nmol/mL, P = 0.045) and superoxide dismutase activity (301.42; 95 % CI (230.63, 372.21) vs. 15.20; 95 % CI (−8.15, 38.55) U/mL, P = 0.009), suggesting potential benefits for migraine management.